<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732442</url>
  </required_header>
  <id_info>
    <org_study_id>JagiellonianU-07</org_study_id>
    <nct_id>NCT04732442</nct_id>
  </id_info>
  <brief_title>Changes in Inflammatory Response After Immunonutrition Compared to Standard Nutrition in Colorectal Cancer Tissue</brief_title>
  <official_title>Changes in Inflammatory Response After Immunonutrition Compared to Standard Nutritional Support in Colorectal Cancer Tissue - Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is Randomized Controlled Trial, in which investigators will estimate the impact of the use&#xD;
      of immunonutrition support compared to standard nutritional support in the preoperative&#xD;
      period in patients with colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first choice of treatment in colorectal cancer is surgery. Nutritional support in form of&#xD;
      oral nutritional supplements (ONS) in the preoperative period is widely accepted in reducing&#xD;
      the incidence of perioperative complications and immunonutrition is generally recommended.&#xD;
      However, there is little clinical data regarding the impact of such treatment on a tumor&#xD;
      biology.&#xD;
&#xD;
      Investigators want to perform Randomized Controlled Trial to explore the impact of the use of&#xD;
      immunonutrition in relation to standard nutritional support in the preoperative period on&#xD;
      alternating the expression of inflammatory response cytokines expression and leukocytes&#xD;
      infiltration in tumor tissue in patients operated for colorectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 2-arm controlled trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in expression of inflammatory cytokines in tumor tissue samples obtained prior and after intervention.</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Expression of following inflammatory cytokines will be measured: Tumor necrosis factor (TNF-α), Interleukin 8 or chemokine (C-X-C motif) ligand (CXCL8), stromal cell-derived factor 1 (SDF-1a), Chemokine (C-X-C motif) ligand 6 (CXCL6), Chemokine (C-X-C motif) ligand 2 (CXCL2), myeloperoxidase (MPO), Chemokine (C-X-C motif) ligand 1 (CXCL1) prior and after intervention. Measurements of cytokines' tissue concentration will be presented in pg/100ug of total protein.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in tissue neutrophil infiltration after preoperative nutritional intervention in tumor tissue samples obtained prior and after intervention.</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Neutrophil infiltration will be assessed by counting the number of neutrophils per 10 large microscopic fields.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Nutrition Aspect of Cancer</condition>
  <arm_group>
    <arm_group_label>Immuno-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The immuno-group will consist of patients who, as part of preoperative nutritional support, used immunonutrition ONS (2x Impact Oral® Nestle, Switzerland per day) for 2 weeks before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control group will consist of patients who, as part of preoperative nutritional support, used standard ONS (3x Fortimel Compact Protein® Nutricia, United Kingdom per day) for 2 weeks before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Immunonutrition</intervention_name>
    <description>Impact Oral® Nestle, Switzerland</description>
    <arm_group_label>Immuno-group</arm_group_label>
    <other_name>Immunonutrition Oral Nutritional Support</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard Oral Nutritional Support</intervention_name>
    <description>Fortimel Compact Protein® Nutricia, United Kingdom</description>
    <arm_group_label>Control-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of colon cancer during preoperative colonoscopy confirmed by&#xD;
             histopathological examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  emergency/urgent operation&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  inflammatory bowel diseases in history&#xD;
&#xD;
          -  other systemic immune disorders&#xD;
&#xD;
          -  the necessity of preoperative neoadjuvant treatment (radiotherapy or chemotherapy)&#xD;
&#xD;
          -  metastatic disease, or local infiltration of cancer which was described as T4 stage in&#xD;
             preoperative CT scan&#xD;
&#xD;
          -  patients who were not able to intake at least 85% of administrated ONS doses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michał Pędziwiatr, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Department of General Surgery, Jagiellonian University Medical College</name>
      <address>
        <city>Kraków</city>
        <state>Małopolska</state>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Michał Pędziwiatr</investigator_full_name>
    <investigator_title>Prof., MD, PhD</investigator_title>
  </responsible_party>
  <keyword>immunonutrition</keyword>
  <keyword>colon cancer</keyword>
  <keyword>inflammatory response</keyword>
  <keyword>perioperative care</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

